Human papillomavirus infection

Worldwide Vaccines Industry to 2029 - Combination Vaccines Remain a Significant Growth Contributor to Vaccine Spaces

Retrieved on: 
Friday, January 6, 2023
SEARO, Influenza, CSL Limited, Vaccine, WPRO, AMRO, Merck, Inactivated vaccine, Projection, COVID-19, Human papillomavirus infection, Pneumococcal conjugate vaccine, Anthrax Vaccine Immunization Program, GSK, Growth, Overalls, Mortality, PCV, Streptococcus pneumoniae, Mitsubishi Tanabe Pharma, Serum Institute of India, HPV, China National Pharmaceutical Group, Emergent BioSolutions, WHO, Chickenpox, Emergent, Conjugate vaccine, Pharmaceutical industry, Sanofi, Pfizer, Waldemar Haffkine

Escalating investments by vaccine manufacturers, and governments from across the globe is predominantly driving the global vaccines market growth.

Key Points: 
  • Escalating investments by vaccine manufacturers, and governments from across the globe is predominantly driving the global vaccines market growth.
  • While vaccines market (excluding COVID-19 vaccine) is expected to demonstrate nearly 11.2% growth, the market (including COVID-19 vaccine) is likely to experience 3.9% growth through the end of forecast period.
  • Epidemic, and pandemic situations like COVID-19 outbreak act as the key growth influencers for vaccines market, says a newly released market intelligence report of The publisher.
  • On the other hand, demand for seasonal influenza vaccines is projected to remain buoyant and will see the fastest growth through 2029.

HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors

Retrieved on: 
Thursday, December 15, 2022
Roche, Paris Diderot University, Micrometer, Arenavirus, Head, Tango, Merck, Global health, Prostate Cancer Foundation, School, CD8, Cancer, Merck & Co., Human papillomavirus infection, HBV, Doctor of Philosophy, Neck, Vaccine, Infection, Internal medicine, Gilead, HIV, Research, Senior, MorphoSys, Development, Patient, Therapy, KRAS, Pharmaceutical industry, Novartis

“Katia has had a major impact on HOOKIPA’s clinical development strategy and execution in immuno-oncology therapeutics and vaccines since she joined the Company in 2021.

Key Points: 
  • “Katia has had a major impact on HOOKIPA’s clinical development strategy and execution in immuno-oncology therapeutics and vaccines since she joined the Company in 2021.
  • “We are also excited to welcome Malte to our Board.
  • She has served as the Company’s Executive Vice President, Clinical Research and Development since July 2022.
  • Dr. Peters serves as Chief Research and Development Officer at MorphoSys and will retire from the company at the end of 2022.

PUBLICIS GROUPE’S ‘USEFUL WISHES’

Retrieved on: 
Tuesday, December 6, 2022
Euronext Paris, Woman, Education, Communication, Vaccination, Marketing, Anal cancer, Cancer, Human papillomavirus infection, Data Intercept Technology Unit, HPV, Cervical cancer, Publicis, Group (military unit), Infection, HPV-associated oropharyngeal cancer awareness and prevention, CAC, Virus, Risk, Prodigy, Partnership, Nightclub, Vaccine

Paris – December 6, 2022 – 2022 has been a stellar year for Publicis on every front.

Key Points: 
  • Paris – December 6, 2022 – 2022 has been a stellar year for Publicis on every front.
  • This is a particularly personal theme for Publicis Groupe CEO Arthur Sadoun as he was diagnosed and treated for HPV-related cancer earlier this year.
  • Publicis Groupe is a privileged partner in its clients’ transformation to enhance personalization at scale.
  • Present in over 100 countries, Publicis Groupe employs around 96,000 professionals.

HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit

Retrieved on: 
Wednesday, November 30, 2022
Gilead, KRAS, Hematology, The, Human papillomavirus infection, Arenavirus, HBV, CD8, Roche, HIV, Prostate cancer, Vaccine

NEW YORK and VIENNA, Austria, Nov. 30, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate virtually in investor meetings and panel discussions at The JMP Securities Hematology and Oncology Summit, December 6 - 7, 2022.

Key Points: 
  • NEW YORK and VIENNA, Austria, Nov. 30, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate virtually in investor meetings and panel discussions at The JMP Securities Hematology and Oncology Summit, December 6 - 7, 2022.
  • HOOKIPAs replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies.
  • HOOKIPAs pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed programs.
  • In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

EQS-News: Defence Therapeutics Inc.: DEFENCE’S SUCCESSFULL STUDY ON THE ACCUVAC-PT007 VACCINE TARGETING CERVICAL CANCER

Retrieved on: 
Sunday, November 27, 2022
Cervical cancer, Human papillomavirus infection, Oropharyngeal cancer, ADC, Tongue, Diagnosis, Pharma, Immune system, Catastrophic illness, Control, Infection, Engineering, Cell, Cancer, Good laboratory practice, Therapy, Partnership, Patient, Mortality, USD, GLP, Vulva, Antigen presentation, Neoplasm, Vaccination, Epithelium, E7, HPV, L1, Wart, CSE, News, Vaccine, Safety, Vagina, Penis, Security (finance), Pharmaceutical industry, Birth control, Defense

Cervical cancer normally occurs when epithelial cells of the cervix are infected with the human papillomavirus (HPV), one of the most common sexually transmitted disease.

Key Points: 
  • Cervical cancer normally occurs when epithelial cells of the cervix are infected with the human papillomavirus (HPV), one of the most common sexually transmitted disease.
  • Currently, vaccination targeting HPV directly can protect from cervical cancer.
  • This vaccine can not only be used to protect from HPV (prophylactic use), but it is the only experimental vaccine capable of curing established cervical cancer when combined to immune-checkpoint inhibitors.
  • Using the AccumTM platform, Defence developed the AccuVAC-PT007, a protein-based vaccine targeting the E7 oncoprotein of the HPV virus.

South America Human Papillomavirus Vaccine Market Analysis/Forecasts Report 2022-2028 Featuring GlaxoSmithKline, Inovio Pharmaceuticals, Merck & Co, R-Pharm, Sanofi, & Serum Institute of India - ResearchAndMarkets.com

Retrieved on: 
Monday, November 21, 2022
Health, Pharmaceutical, Cervical cancer, Hospital, Wart, Laboratory, Human papillomavirus infection, Cancer, HPV, Biomarker, Research, Woman, Disease, Public health, COVID-19, Risk, BD, Center for Urban and Regional Analysis, Vaccine, Dose, Application

This factor is likely to drive the South America human papillomavirus (HPV) vaccine market .

Key Points: 
  • This factor is likely to drive the South America human papillomavirus (HPV) vaccine market .
  • The South America human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.
  • In terms of dosage, the South America human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose.
  • In terms of application, the South America human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts.

Australian Scientists Honoured with the Grand Hamdan Award

Retrieved on: 
Thursday, November 24, 2022
Future, Human papillomavirus infection, Cervical cancer, Museum, Late, Award, Sheikh Rashid bin Saeed Crossing, University, Medical research, Multimedia, Faculty of Medicine, University of Malaya, Museum of the Future (Dubai), HPV, University of Queensland, Faculty, Immunology, Translational Research Institute, Hamdan, Research, Infection, TRI, Pharmaceutical industry, Medicine

DUBAI, UAE, Nov. 24, 2022 /PRNewswire/ -- The Award ceremony of the Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences, hosted in Dubai, took place on 23rd of November the Museum of the Future.

Key Points: 
  • DUBAI, UAE, Nov. 24, 2022 /PRNewswire/ -- The Award ceremony of the Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences, hosted in Dubai, took place on 23rd of November the Museum of the Future.
  • The Award celebrated its 12th term (2021-2022) and 22nd year, in the presence of Sheikh Rashid bin Hamdan bin Rashid Al Maktoum, who personally awarded the 14 winners.
  • Prof. Ian Hector Frazer and Late Dr. Jian Zhou were awarded with the prestigious Grand Hamdan Award in the field of Infectious Diseases.
  • Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences is a non-profit organization that honors researchers worldwide who carry out distinguished medical research to serve humanity.

Repertoire® Immune Medicines Presents New Data From Its DECODE™ Platform Identifying Highly Prevalent Immunotherapeutic Targets in HPV-Positive Cancers, Unlocking Pathways for Potential Therapeutics

Retrieved on: 
Thursday, November 10, 2022
Oncology, Health, Other Health, Research, Science, Pharmaceutical, Biotechnology, Repertoire, Flagship Pioneering, Head, Epitope, Prevalence, Human papillomavirus infection, Annual general meeting, EST, Immunotherapy, Interleukin, Research, Cancer, Center, Technology, Development, Population, HPV, CD8, Dana–Farber Cancer Institute, Society for Immunotherapy of Cancer, Haplotype, B cell, Infection, SITC, E7, HLA, Neoplasm, Research and development, E5, OPSCC, Patient, Autoimmune disease, TCR, Society, Degenerative disease, Antigen, Vaccine, E6, Poster

Importantly, we now have data that point to antigens active in driving these malignancies, which we can use to develop novel targeted medicines.

Key Points: 
  • Importantly, we now have data that point to antigens active in driving these malignancies, which we can use to develop novel targeted medicines.
  • DECODE is being used to assess the immunogenicity profile of HPV 16 and HPV 33-positive tumors in oropharyngeal squamous cell carcinoma (OPSCC).
  • Using the DECODE platform, we have a window into the mechanisms involved in the immune surveillance of cancer, which offers us the ability to develop highly selective immune-based medicines, said Anthony Coyle, Ph.D., President, Research and Development, Repertoire Immune Medicines.
  • Repertoire intends to utilize these insights into key drivers that govern immune function to design and develop novel immune product candidates.

New Canadian Cancer Statistics report reveals over 1.5 million people in Canada are living with or beyond cancer

Retrieved on: 
Tuesday, November 8, 2022
People, Canadian Partnership Against Cancer, Diagnosis, Investment, Registry, Statistics Canada, BRCA2, Human, Public Health Agency of Canada, Cancer Institute of New South Wales, Optimism, Growth, Patient, Canadian Cancer Society, Surveillance, Cancer, Radiation, Mortality, CCS, Population, Survival, Government, Income, Public Health Agency, Cervical cancer, Songololo: Voices of Change, Disease, Life, Statistics, Vital statistics, CCPS, Breast cancer, Method, Center, COVID-19, Survivor, BRCA1, Prostate cancer, Human voice, Ageing, Hotel manager, Incidence, Prostate, HPV, Prevalence, Solution, Research, Human papillomavirus infection, American Cancer Society, Quality of life, Risk, Breast, Pharmaceutical industry, Medical imaging, Dietary supplement, Medical device, Vaccine, Health insurance

The report Canadian Cancer Statistics: A 2022 special report on cancer prevalence wasdeveloped by the Canadian Cancer Statistics Advisory Committee incollaboration with CCS,Statistics Canada and the Public Health Agency of Canada.

Key Points: 
  • The report Canadian Cancer Statistics: A 2022 special report on cancer prevalence wasdeveloped by the Canadian Cancer Statistics Advisory Committee incollaboration with CCS,Statistics Canada and the Public Health Agency of Canada.
  • Statistics Canada is proud to contribute to the Canadian Cancer Statistics report, which provides insight into the services and research required to better support the 1.5 million people living with cancer in Canada.
  • Canadian Cancer Statisticsis developed through a collaboration of the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada.Cancer incidence and mortality data are from the Canadian Cancer Registry and the Canadian Vital Statistics Death databases, respectively, which are maintained at Statistics Canada.
  • We provide a compassionate support system for all those affected by cancer, across Canada and for all types of cancer.

HOOKIPA to Participate in the Sidoti Micro-Cap Virtual Conference

Retrieved on: 
Wednesday, November 2, 2022
CD8, Gilead, HIV, KRAS, Conference, GLOBE, Arenavirus, Roche, HBV, Human papillomavirus infection, NASDAQ, Prostate Cancer Foundation, Investor, Sidoti, Vaccine

NEW YORK and VIENNA, Austria, Nov. 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in the Sidoti Micro-Cap Virtual Conference, November 9 - 10, 2022.

Key Points: 
  • NEW YORK and VIENNA, Austria, Nov. 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in the Sidoti Micro-Cap Virtual Conference, November 9 - 10, 2022.
  • The webcast of the presentation will be available within the Investors & Media section of HOOKIPAs website at https://ir.hookipapharma.com/events.
  • HOOKIPAs pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed programs.
  • In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.